ClinicalTrials.gg
RecruitingNCT07213219RBD ImpulseUpdated Jul 8, 2026

PET-MRI of Reward System in Parkinson's Disease With RBD

An interventional study of PET-MRI (Positron Emission Tomography - Magnetic Resonance Imaging). in Parkinson's Disease (PD), sponsored by University Hospital, Clermont-Ferrand. Recruiting at 3 sites in France. Open to participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Non-randomized
Ages
45 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Disruptive, Impulse Control, and Conduct Disorders with a site in France — 3 open to participants now, 3 under way, none of them phase 3. Disruptive, Impulse Control, and Conduct Disorders · France.

Started
2026
with 1 other
No phase
5 of 12
2 open now
Registered
11th of 12
by date
Lead sponsor
4 of 12
University Hospital, Clermont-Ferrand

Among the 12 studies in Disruptive, Impulse Control, and Conduct Disorders with a site in France, this one is one of 2 that started in 2026, is one of 5 with no phase, and was the 11th registered.

Disruptive, Impulse Control, and Conduct Disorders

56 studies on the registry are indexed under Disruptive, Impulse Control, and Conduct Disorders; 17 are open to participants now.

Browse Disruptive, Impulse Control, and Conduct Disorders studies →

Open to participants now

3 of the 12 studies in Disruptive, Impulse Control, and Conduct Disorders with a site in France are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 15 Disruptive, Impulse Control, and Conduct Disorders studies recruiting now, 4 (27%) set no upper age limit and 10 (67%) stop at 75 or younger; none take children under 18; 5 take healthy volunteers.

This study: 45 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Disruptive, Impulse Control, and Conduct Disorders with a site in France, or all of them as a file.
02

Study summary

Impulse control disorders (ICDs) are frequently observed in Parkinson's disease (PD) and can have a major functional impact on the quality of life of both the patient and their entourage. The primary risk factor for the emergence of ICDs in PD is long-term dopaminergic treatment, but other risk factors, such as rapid eye movement sleep behavior disorder (RBD), have recently been identified. The mechanisms leading to ICDs in PD remain debated, but it has been shown that the dopaminergic mesocorticolimbic pathways play a key role in reward, learning, and reinforcement processes, as well as in the regulation of impulsivity. PET studies using [11C]raclopride, a tracer that allows evaluation of the postsynaptic availability of dopamine D2/D3 receptors, have demonstrated abnormal sensitization of the mesocorticolimbic dopaminergic system (the reward system), particularly in the ventral striatum, in Parkinson's patients with ICDs when presented with appetitive stimuli or during gambling tasks. However, this has never been studied in patients with and without RBD. Parkinson's patients with RBD may present greater impairment of mesocorticolimbic pathways than those without RBD, particularly abnormal sensitization and postsynaptic modifications of the dopaminergic system, which could predispose patients to the emergence of ICDs when exposed to dopaminergic agonists. Confirming a particular pattern of denervation in Parkinson's patients with RBD that may favor the emergence of ICDs constitutes a personalized medicine approach with a readily identifiable risk marker in routine clinical practice and offers the possibility of adapting the management of these patients.

The main objective of this study is to investigate the availability of D2 dopaminergic receptors in subcortical structures (particularly the mesocorticolimbic system) in patients with idiopathic Parkinson's disease, depending on the presence or absence of RBD

03

Conditions studied

  • Parkinson's Disease (PD)

Keywords

  • Impulse Control Disorders
  • Rapid Eye Movement Sleep Behavior Disorder
  • Parkinson's Disease
  • Positron Emission Tomography
  • [¹¹C]raclopride
  • Magnetic Resonance Imaging
04

Who can participate

Ages eligible
45 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 45 to 80 years
  • Patients diagnosed with idiopathic Parkinson's disease (PD) according to the Movement Disorder Society criteria
  • Duration of Parkinson's disease progression ≥ 3 years
  • Patients receiving chronic dopaminergic treatment including levodopa for at least one year to avoid tolerance issues during acute levodopa administration
  • Ability to cooperate and understand, allowing strict compliance with the conditions set forth in the protocol
  • Patients affiliated with or beneficiaries of a social security system
  • Volunteer patients capable of providing to participate in the research

Exclusion criteria

Exclusion Criteria:

  • Patients suffering from neurological disorders other than idiopathic Parkinson's disease (PD)
  • Patients with severe depression (Beck Depression Inventory \[20] (BDI) score > 30), apathy (Starkstein scale \[21] score ≥ 14), cognitive impairment ( \[MoCA] \[22] score \< 25).
  • Patients with impulse control disorders, defined by either of the following:

    • A score of ≥ 6 on the "Pathological Gambling" item, ≥ 8 on the "Compulsive Buying" item, ≥ 8 on the "Sexual Behavior" item, or ≥ 7 on the "Eating Behavior" item, and more than one positive response (score > 0) on the corresponding QUIP-RS items for Gambling, Compulsive Buying, Sexual Behavior, and Eating Behavior.
    • A total QUIP-RS score ≥ 10.
  • Patients with severe motor symptoms: patients with an MDS-UPDRS III score > 45 will be excluded to avoid severe discomfort or interfering tremor (tremor item ≥ 3 in any body part) in the OFF state during PET-MRI acquisition. Patients with severe dyskinesias will also be excluded due to technical issues related to movement
  • Patients under guardianship, curatorship, deprived of liberty, or under legal protection
  • Pregnant or breastfeeding women
  • Patients with to PET-MRI (e.g., those with pacemakers or insulin pumps, metallic prostheses or intracerebral clips, claustrophobia, neurosensorial stimulators or implantable defibrillators, cochlear implants, ferromagnetic ocular or cerebral foreign bodies near nervous structures, uncooperative or agitated patients, neurosurgical ventriculoperitoneal shunts, dental appliances)
  • Refusal to participate
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    MPI with RBD

    Other: PET-MRI (Positron Emission Tomography - Magnetic Resonance Imaging).

  • Experimental
    MPI without RBD

    control group

    Other: PET-MRI (Positron Emission Tomography - Magnetic Resonance Imaging).

Interventions

  • OtherPET-MRI (Positron Emission Tomography - Magnetic Resonance Imaging).

    The PET-MRI will be performed using a Siemens Biograph mMR hybrid PET-MRI scanner. A 60-minute dynamic PET acquisition will begin following the intravenous injection of \\\[¹¹C\]raclopride (a radiotracer agonist of dopamine D2/D3 receptors) synthesized in the radiopharmaceutical laboratories of CERMEP. Simultaneously with the PET acquisition, brain MRI sequences will be acquired: 3D anatomical T1 and 3D T2, SWI, diffusion MRI (DTI), resting-state functional MRI, and arterial spin labeling (ASL) perfusion MRI. Patients will undergo two PET-MRI scans on two consecutive days under two pharmacological conditions: Off and On dopamine: * Day 1:\*\* The first PET-MRI session (TEPDopaOff) will be performed after a 12-hour withdrawal from usual dopaminergic treatment (Off dopamine). * Day 2:\*\* The second PET-MRI session (TEPDopaOn) will be similar to the first, except it will take place 1 hour after administration of immediate-release Levodopa

06

What researchers measure

Primary outcomes

  1. [¹¹C]raclopride binding potential (BP, unitless) measured with PET-MRI in mesocorticolimbic brain structures between participants with and without RBD, off treatment.

    The primary outcome measure corresponds to the Difference in binding potential (BP) of \[¹¹C\]raclopride in the brain structures of the mesocorticolimbic network between groups with and without RBD at baseline evaluation, off treatment, derived from PET-MRI imaging in mesocorticolimbic brain structures. The measurement tool is the \[¹¹C\]raclopride PET-MRI. BP is a unitless quantitative parameter (ratio between specifically bound radioligand and non-displaceable radioligand in tissue).

    Time frame: During MRI exploration (3 months after inclusion visit)

Secondary outcomes

  1. [¹¹C]raclopride binding potential (BP, unitless) measured with PET-MRI in mesocorticolimbic brain structures between participants with and without RBD following acute administration of Levodopa

    Time frame: During MRI exploration (3 months after inclusion visit)

  2. MDS-UPDRS III motor score

    UPPS impulsivity scale score

    Time frame: at the inclusion visit

  3. Starkstein apathy scale score

    Time frame: at inclusion visit

  4. BDI depression score

    Time frame: at inclusion visit

  5. Ardouin Scale of Behavior in Parkinson's Disease) scores (hypodopaminergic and hyperdopaminergic items)

    Time frame: at inclusion visit

  6. Total levodopa equivalent dose and for agonists (in mg/day)

    Time frame: at inclusion visit

  7. Voxel-wise parametric statistical maps (SPM) across the whole brain comparing PET parametric images ([¹¹C]raclopride BP)

    Time frame: During MRI exploration (3 months after inclusion visit)

  8. Voxel-wise parametric statistical maps (SPM) across the whole brain comparing MRI images.

    Time frame: During MRI exploration (3 months after inclusion visit)

07

Study locations

3 of 3 sites recruiting
  • CHU Clermont-Ferrand, Clermont-Ferrand,
    Clermont-Ferrand, 63000, France
    Recruiting
  • CH Le Puy en Velay
    Le Puy-en-Velay, France
    Recruiting
    • Jeremy DASSA · Principal investigator
  • CHRU Lyon
    Lyon, France
    Recruiting
    • Stéphane THOBOIS · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for Jan 2028, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2025
First posted
Oct 8, 2025
StartActual
May 7, 2026
Primary completionEst.
Jan 1, 2028
CompletionEst.
Jan 1, 2029
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07213219
Responsible party
Sponsor
First posted
Oct 8, 2025
Start date
May 7, 2026
Primary completion
Jan 1, 2028 (estimated)
Completion
Jan 1, 2029 (estimated)
Last update
Jul 8, 2026

Study contacts

Lise LACLAUTRE
Contact
promo_interne_drci@chu-clermontferrand.fr
+334.73.754.963
Charlotte BEAL
principal investigator · University Hospital, Clermont-Ferrand

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion